Reconnecting

The current page stays visible while onset.to reconnects in the background.

MAPS PBC Introduction by CEO Amy Emerson

Open original

The Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation leads efforts to establish MDMA-assisted psychotherapy as an approved prescription treatment. By prioritizing public benefit over narrow profit motives, the organization systematically navigates the FDA drug development process. Following promising late-phase results showing statistically significant symptom reduction among treatment-resistant populations, clinical focus has shifted toward confirmatory stage-three research studies. Beyond central trials, expanded access programs, sometimes referred to as compassionate use, facilitate broader therapeutic engagement as researchers work toward long-term approval. The organization also supports investigator-initiated studies, allowing external researchers to develop independent MDMA-focused programs with foundational expertise and supply support.